Brensocatib

Brensocatib (sold under the brand name Brinsupri) is a first-in-class, oral medication used for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients aged 12 years and older. It was approved by the US FDA on August 12, 2025, and by the European Union in November 2025